Background Little is known about the impact of exacerbations on COPD progression or
whether inhaled corticosteroid (ICS) use and blood eosinophil count (BEC) affect …

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease
and its definition as a disease characterised by a non completely reversible airflow …

Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol
(SAL)(combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Background Treatment with systemic corticosteroids in patients with acute exacerbations of
chronic obstructive pulmonary disease (COPD) is associated with debilitating adverse …

Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous
disorder that is responsible for substantial and growing morbidity, mortality, and health-care …

Chronic obstructive pulmonary disease (COPD) is a major cause of ill health and medical
expenditure worldwide. Despite recent increases in the knowledge about the nature of the …

Abstract Background Clinically Important Deterioration (CID) is a novel composite measure
to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined …

Introduction: The aim was to investigate how the pattern of pharmacological treatment in
Swedish patients with chronic obstructive pulmonary disease (COPD) has changed over a …

Introduction: Current guidelines recommend the use of inhaled long-acting bronchodilators,
inhaled corticosteroids (ICSs) and their combinations for maintenance treatment of moderate …